Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia Mar 2, 2026 08:30AM
Gilead Sciences to Present at Upcoming Investor Conferences Feb 23, 2026 04:05PM
Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend Feb 10, 2026 04:02PM
Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026 Jan 27, 2026 04:05PM
Gilead's Trodelvy plus Keytruda shows 35% reduction in cancer progression Jan 21, 2026 05:00PM
View Older Stories

Jan 21, 2026 05:00PM New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negativ
Dec 24, 2025 07:00AM Gilead Sciences acquires Repare drug candidate for up to $30 million
Dec 22, 2025 04:05PM Gilead Sciences to Present at Upcoming Investor Conference
Dec 22, 2025 08:02AM Gilead exercises option for Assembly Bio's herpes treatment programs
Dec 22, 2025 08:00AM Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
Dec 19, 2025 02:21PM GILEAD reaches three-year pricing agreement with US government
Dec 19, 2025 02:21PM Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
Dec 18, 2025 08:30AM Gilead Sciences names Keeley Wettan as executive vice president
Dec 18, 2025 08:30AM Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
Dec 9, 2025 08:30AM Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
Dec 8, 2025 02:53AM Kite reports 96% response rate in multiple myeloma trial
Dec 6, 2025 02:00PM Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
Nov 24, 2025 08:30AM Gilead Foundation Commits Over $3 Million to Address Food Insecurity
Nov 18, 2025 05:09AM Gilead ships first lenacapavir doses to sub-Saharan Africa
Nov 18, 2025 05:00AM Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
Nov 7, 2025 08:30AM Gilead's Trodelvy fails to meet primary endpoint in breast cancer study
Nov 7, 2025 08:30AM Gilead Provides Update on Phase 3 ASCENT-07 Study
Nov 7, 2025 08:01AM GILD presents long-term data on Livdelzi for liver disease treatment
Nov 7, 2025 08:00AM Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
Nov 4, 2025 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Nov 3, 2025 09:10AM Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
Oct 31, 2025 08:00AM Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
Oct 23, 2025 08:00AM Gilead to present liver disease data at AASLD conference
Oct 23, 2025 08:00AM Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta
Oct 19, 2025 08:30AM Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
Oct 19, 2025 02:30AM Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
Oct 13, 2025 08:32AM Gilead to present Trodelvy breast cancer data at ESMO 2025
Oct 13, 2025 08:30AM Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
Oct 9, 2025 04:05PM Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
Sep 25, 2025 08:00AM Gilead Foundation Grants $6.5 Million in Commitment to STEM Education
Sep 4, 2025 02:15PM Gilead partners with PEPFAR to deliver HIV prevention drug to 2 million people
Sep 4, 2025 02:15PM Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
Sep 3, 2025 11:32AM Gilead Sciences breaks ground on new manufacturing facility in Foster City
Sep 3, 2025 11:30AM Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy
Aug 26, 2025 03:00AM European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
Aug 20, 2025 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Jul 25, 2025 05:58AM Gilead receives positive EU opinion for twice-yearly HIV prevention drug
Jul 25, 2025 03:00AM Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention
Jul 24, 2025 04:05PM Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Jul 14, 2025 09:31AM Gilead presents data on twice-yearly HIV prevention drug at IAS 2025
Jul 14, 2025 09:30AM Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025
Jul 9, 2025 08:00AM Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
Jun 25, 2025 07:02AM Gilead Sciences (GILD) and Kymera Therapeutics (KYMR) Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
Jun 25, 2025 07:00AM Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
Jun 18, 2025 02:50PM Gilead Sciences (GILD): Yeztugo Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
Jun 18, 2025 02:49PM Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
May 31, 2025 08:00AM Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
May 23, 2025 08:32AM Gilead Sciences (GILD) announces positive data from Phase 3 Trodelvy study
May 23, 2025 08:30AM ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast C
May 15, 2025 04:15PM Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Th
View Older Stories